What is fluticasone?

What is Fluticasone?

Fluticasone is a synthetic, trifluorinated corticosteroid medication with potent anti-inflammatory activity, available in multiple formulations (propionate and furoate) for treating inflammatory conditions of the airways and nasal passages, including asthma and allergic rhinitis. 1

Pharmacological Properties

Fluticasone functions as a glucocorticoid receptor agonist with exceptionally high receptor affinity and selectivity. The drug demonstrates 3- to 5-fold greater potency than dexamethasone in receptor binding studies 1. Its mechanism involves suppressing multiple inflammatory pathways by affecting various cell types (mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (histamine, leukotrienes, cytokines) 1.

Key pharmacokinetic advantages include:

• Minimal systemic absorption: Intranasal bioavailability <2%, oral bioavailability negligible 1
• Rapid hepatic metabolism: High first-pass clearance (1,093 mL/min) 1
• High tissue binding: 91% protein-bound, volume of distribution 4.2 L/kg 1
• Low systemic exposure: Reduces risk of systemic corticosteroid side effects 1

The drug's lipophilic nature allows strong binding to lung tissue with a receptor complex half-life exceeding 10 hours, providing sustained anti-inflammatory effects 2.

Clinical Formulations and Uses

Intranasal Formulations

Fluticasone propionate nasal spray (50 mcg/spray) is FDA-approved for treating allergic and non-allergic rhinitis in patients ≥4 years 3. Intranasal corticosteroids, including fluticasone, represent the most effective medication class for allergic rhinitis, superior to combined antihistamine-leukotriene antagonist therapy 4.

The intranasal formulation demonstrates:

• Onset of action: 3-12 hours, with some patients experiencing relief within 3-4 hours 4
• Efficacy for all four cardinal symptoms: sneezing, itching, rhinorrhea, and nasal congestion 4
• Effectiveness in non-allergic rhinitis subtypes (NARES, vasomotor rhinitis) 4
• Benefit for ocular allergy symptoms associated with allergic rhinitis 4

Inhaled Formulations for Asthma

Fluticasone is available as:

• Fluticasone propionate: MDI (44,110,220 mcg/puff) and DPI (50,100,250 mcg/inhalation) 5
• Fluticasone furoate: Once-daily formulation, including combination with vilanterol (LABA) 6

For asthma management, fluticasone demonstrates at least twice the potency of beclomethasone dipropionate, budesonide, or triamcinolone acetonide 7. The drug effectively improves both objective measures (lung function) and subjective outcomes (symptoms, quality of life) across the asthma severity spectrum 7.

Safety Profile

At recommended doses, fluticasone demonstrates an excellent safety profile with minimal clinically significant systemic effects 4.

Systemic Effects

Studies in children and adults show no consistent, clinically relevant effects on:

• Hypothalamic-pituitary-adrenal (HPA) axis function 4
• Ocular pressure or cataract formation 4
• Bone mineral density 4

Growth considerations in children: Fluticasone propionate and mometasone furoate show no effect on growth at recommended doses compared to placebo, even at twice the recommended doses 4. Growth suppression has only been reported with beclomethasone dipropionate exceeding recommended doses or in toddlers 4.

Local Side Effects

Local adverse effects are rare and preventable with proper technique 4:

• Nasal irritation or burning (especially with propylene glycol-containing preparations)
• Epistaxis (blood-tinged secretions)
• Nasal septal perforation (rare, with long-term use) 4

Critical administration technique: Direct spray away from the nasal septum; periodic examination of the septum is recommended to detect early mucosal erosions 4.

For inhaled formulations, common local effects include oral candidiasis, dysphonia, and cough—minimized by using spacers and mouth rinsing after use 5.

Clinical Considerations

Proper patient counseling is essential: Fluticasone, like other corticosteroids, does not provide immediate symptom relief 1. Maximum benefit may require several days of consistent use 4. When discontinued, symptoms may not return immediately for several days 1.

Drug interactions: Fluticasone is metabolized via cytochrome P450 3A4. Coadministration with potent CYP3A4 inhibitors (ritonavir, ketoconazole) is not recommended due to potential for increased systemic exposure and Cushing syndrome 1, 5.

The combination of fluticasone with other agents (azelastine for rhinitis, vilanterol for asthma) provides enhanced efficacy for patients with moderate-to-severe disease 8, 6.